Lilly has entered into a global licensing and collaboration agreement with Repertoire Immune Medicines, securing exclusive rights to advance Repertoire’s early‑stage discoveries into novel tolerising therapies targeting multiple autoimmune diseases. The deal, valued at up to US$1.9 B, allows Lilly to lead the clinical development, manufacturing, and commercialisation of candidates emerging from Repertoire’s DECODETM T‑cell receptor–epitope discovery platform. This partnership strengthens Lilly’s expanding immunology pipeline while enabling Repertoire to scale its precision‑immunology approach using Lilly’s global development expertise and commercial reach.